No Data
No Data
Truist Securities: Maintains Allogene Therapeutics (ALLO.US) rating, adjusted from buy to buy rating, target price $17.00.
Truist Securities: Maintains Allogene Therapeutics (ALLO.US) rating, adjusted from buy to buy rating, target price $17.00.
Truist Securities Maintains Buy on Allogene Therapeutics, Maintains $17 Price Target
Truist Securities analyst Asthika Goonewardene maintains Allogene Therapeutics with a Buy and maintains $17 price target.
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results.Arcutis Biotherapeutics
Analysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), Allogene Therapeutics (ALLO)
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 20 points on Wednesday.Shares of DLocal Limited (NASDAQ:DLO) fell sharply in today's pre-market trading after
Allogene Therapeutics Files For Offering Of Up To 37.93M Shares Of Common Stock
Allogene Therapeutics Files For Offering Of Up To 37.93M Shares Of Common Stock